Company: NEOG
Filing Date: 2025-08-14
Form Type: 8-K
Source: 0000950170-25-108900
Chunk: 0

Company: NEOGEN CORP
Filing Date: 2025-08-14
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Retirement of Director

On August 11, 2025, William T. Boehm notified Neogen Corporation (the “ Company”) that he would be retiring from the Company’s Board of Directors when his term ends on October 23, 2025. Dr. Boehm has served on Neogen’s Board since 2011 and currently chairs the Audit Committee and serves on the Compensation & Talent Management Committee.

(d) Appointment of New Director

On August 14, 2025, the Company’s Board of Directors appointed Avi Pelossof to the Board, effective October 24, 2025. Mr. Pelossof will serve as a Class II director. Mr. Pelossof will participate in the Company's non-employee director compensation program. A description of the Company's non-employee director compensation program is set forth under the heading “ Director Compensation” in the Company's proxy statement for the 2024 Annual Meeting of Shareholders, filed with the Securities and Exchange Commission (SEC) on September 13, 2024, and that section of the proxy statement is incorporated herein by this reference.

Mr. Pelossof has over 25 years of experience in the diagnostics market. He most recently served as Chief Executive Officer, President, and as a member of the Board of Directors at Immucor Inc., where he led the company’s turnaround and its acquisition by Werfen in 2023. He previously served as Global President, Infectious Disease at Alere Inc., where he built the business into a $750 million global portfolio and launched the first FDA CLIA-waived point-of-care molecular test, now marketed by Abbott as ID NOW.

There are no arrangements or understandings between Mr. Pelossof and any other person pursuant to which he was selected as a director, nor are there any transactions or currently proposed transactions involving the Company in which Mr. Pelossof has a material interest that would be required to be disclosed pursuant to SEC rules.

Item 8.01 Other Events.